Oral Presentation Australasian RNA Biology and Biotechnology Association 2026 Conference

SOF-SKN, A TOPICAL OLIGONUCLEOTIDE TOLL-LIKE RECEPTOR 7/8 INHIBITOR: RESULTS FROM A FIRST-IN-HUMAN PHASE 1A/B STUDY (143303)

Michaela Bennett 1 , Marissa Lim 2 3 , Lorena Figueroa 2 3 , Daniel S Wenholz 2 3 , Mary Speir 2 3 , John Wilkinson 2 3 , Gisela Mautner 2 3 , Olivier F Laczka 2 3
  1. Doherty Clinical Trials, Melbourne
  2. Noxopharm Ltd, Castle Hill, NSW, Australia
  3. Pharmorage Pty ltd, Sydney, NSW, Australia
Publish consent withheld